Literature DB >> 28193655

Application of Fluoroquinolone Resistance Score in Management of Complicated Urinary Tract Infections.

Ansal Shah1,2, Julie Ann Justo3,4, P Brandon Bookstaver3,4, Joseph Kohn4, Helmut Albrecht1,2, Majdi N Al-Hasan5,2.   

Abstract

The fluoroquinolone resistance score (FQRS) predicts the probability of fluoroquinolone resistance with good discrimination. The score has been derived from patients with bloodstream infections caused by Gram-negative bacteria and is based on fluoroquinolone use within the past 6 months, among other clinical and health care exposure criteria. This study aims to examine the utility of the FQRS in patients with complicated urinary tract infections (cUTI) and determine whether extension of prior fluoroquinolone use to 12 months improves model discrimination. Adults with cUTI at Palmetto Health in central South Carolina, USA, from 1 April 2015 through 31 July 2015 were prospectively identified. Multivariate logistic regression was used to examine the association between prior fluoroquinolone use and resistance. Among 238 patients, 54 (23%) had cUTI due to fluoroquinolone-resistant bacteria. Overall, the median age was 66 years, 162 (68%) patients were women, and 137 (58%) patients had cUTI due to Escherichia coli Prior exposure to fluoroquinolones within 3 months (adjusted odds ratio [aOR], 23.4; 95% confidence interval [CI], 8.2 to 76.8; P < 0.001) and within 3 to 12 months (aOR, 13.2; 95% CI, 3.1 to 68.4; P < 0.001) was independently associated with fluoroquinolone resistance compared to no prior use. The area under the receiver operating characteristic curve for the FQRS increased from 0.73 to 0.80 when prior fluoroquinolone use was extended from 6 to 12 months. FQRSs of ≥2 and ≥3 had negative predictive values of 91% and 90%, respectively. The modified FQRS stratifies patients with cUTI on the basis of the predicted probability of fluoroquinolone resistance with very good discrimination. Application of the modified FQRS may improve antimicrobial utilization in patients with acute pyelonephritis.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  bacteremia; bloodstream infections; ciprofloxacin; levofloxacin; pyelonephritis; risk factors; sepsis

Mesh:

Substances:

Year:  2017        PMID: 28193655      PMCID: PMC5404571          DOI: 10.1128/AAC.02313-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  Critical review of current definitions of urinary tract infections and proposal of an EAU/ESIU classification system.

Authors:  Truls E Bjerklund Johansen; Henry Botto; Mete Cek; Magnus Grabe; Peter Tenke; Florian M E Wagenlehner; Kurt G Naber
Journal:  Int J Antimicrob Agents       Date:  2011-10-21       Impact factor: 5.283

2.  Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).

Authors:  Florian M Wagenlehner; Obiamiwe Umeh; Judith Steenbergen; Guojun Yuan; Rabih O Darouiche
Journal:  Lancet       Date:  2015-04-27       Impact factor: 79.321

3.  Impact of fluoroquinolone resistance in Gram-negative bloodstream infections on healthcare utilization.

Authors:  M M Brigmon; P Brandon Bookstaver; J Kohn; H Albrecht; M N Al-Hasan
Journal:  Clin Microbiol Infect       Date:  2015-05-21       Impact factor: 8.067

Review 4.  International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.

Authors:  Kalpana Gupta; Thomas M Hooton; Kurt G Naber; Björn Wullt; Richard Colgan; Loren G Miller; Gregory J Moran; Lindsay E Nicolle; Raul Raz; Anthony J Schaeffer; David E Soper
Journal:  Clin Infect Dis       Date:  2011-03-01       Impact factor: 9.079

5.  Fluoroquinolone-resistant Escherichia coli sequence type 131 isolates causing bloodstream infections in a canadian region with a centralized laboratory system: rapid emergence of the H30-Rx sublineage.

Authors:  Gisele Peirano; Johann D D Pitout
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

6.  Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial.

Authors:  D A Talan; W E Stamm; T M Hooton; G J Moran; T Burke; A Iravani; J Reuning-Scherer; D A Church
Journal:  JAMA       Date:  2000 Mar 22-29       Impact factor: 56.272

Review 7.  The epidemiology of urinary tract infection.

Authors:  Betsy Foxman
Journal:  Nat Rev Urol       Date:  2010-12       Impact factor: 14.432

8.  Antimicrobial resistance trends of Escherichia coli bloodstream isolates: a population-based study, 1998-2007.

Authors:  Majdi N Al-Hasan; Brian D Lahr; Jeanette E Eckel-Passow; Larry M Baddour
Journal:  J Antimicrob Chemother       Date:  2009-05-12       Impact factor: 5.790

9.  Escherichia coli sequence type 131 is a dominant, antimicrobial-resistant clonal group associated with healthcare and elderly hosts.

Authors:  Ritu Banerjee; Brian Johnston; Christine Lohse; Stephen B Porter; Connie Clabots; James R Johnson
Journal:  Infect Control Hosp Epidemiol       Date:  2013-02-13       Impact factor: 3.254

10.  Same Exposure but Two Radically Different Responses to Antibiotics: Resilience of the Salivary Microbiome versus Long-Term Microbial Shifts in Feces.

Authors:  Egija Zaura; Bernd W Brandt; M Joost Teixeira de Mattos; Mark J Buijs; Martien P M Caspers; Mamun-Ur Rashid; Andrej Weintraub; Carl Erik Nord; Ann Savell; Yanmin Hu; Antony R Coates; Mike Hubank; David A Spratt; Michael Wilson; Bart J F Keijser; Wim Crielaard
Journal:  MBio       Date:  2015-11-10       Impact factor: 7.867

View more
  4 in total

Review 1.  Advances in novel antibiotics to treat multidrug-resistant gram-negative bacterial infections.

Authors:  Aaron Matlock; Joshua Allan Garcia; Kayvan Moussavi; Brit Long; Stephen Yuan-Tung Liang
Journal:  Intern Emerg Med       Date:  2021-05-06       Impact factor: 5.472

2.  Prevalence of quinolone-resistant uropathogenic Escherichia coli in a tertiary care hospital in south Iran.

Authors:  Yalda Malekzadegan; Elham Rastegar; Melika Moradi; Hamid Heidari; Hadi Sedigh Ebrahim-Saraie
Journal:  Infect Drug Resist       Date:  2019-06-19       Impact factor: 4.003

3.  Retrospective Cohort Study of the 12-Month Epidemiology, Treatment Patterns, Outcomes, and Health Care Costs Among Adult Patients With Complicated Urinary Tract Infections.

Authors:  Thomas P Lodise; Janna Manjelievskaia; Elizabeth Hoit Marchlewicz; Mauricio Rodriguez
Journal:  Open Forum Infect Dis       Date:  2022-06-20       Impact factor: 4.423

4.  Fluoroquinolone resistant bacterial isolates from the urinary tract among patients attending hospitals in Bushenyi District, Uganda.

Authors:  Martin Odoki; Adamu Almustapha Aliero; Julius Tibyangye; Josephat Nyabayo Maniga; Emmanuel Eilu; Ibrahim Ntulume; Eddie Wampande; Charles Drago Kato; Ezera Agwu; Joel Bazira
Journal:  Pan Afr Med J       Date:  2020-06-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.